Barinthus Biotherapeutics (BRNS) Competitors $1.45 +0.03 (+1.79%) Closing price 10/3/2025 03:57 PM EasternExtended Trading$1.45 +0.00 (+0.32%) As of 10/3/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BRNS vs. CRBU, VOR, MIST, IPHA, ACTU, ENTA, TVGN, NVCT, GLSI, and NLTXShould you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Caribou Biosciences (CRBU), Vor Biopharma (VOR), Milestone Pharmaceuticals (MIST), Innate Pharma (IPHA), Actuate Therapeutics (ACTU), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Nuvectis Pharma (NVCT), Greenwich LifeSciences (GLSI), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry. Barinthus Biotherapeutics vs. Its Competitors Caribou Biosciences Vor Biopharma Milestone Pharmaceuticals Innate Pharma Actuate Therapeutics Enanta Pharmaceuticals Tevogen Bio Nuvectis Pharma Greenwich LifeSciences Neoleukin Therapeutics Barinthus Biotherapeutics (NASDAQ:BRNS) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Is BRNS or CRBU more profitable? Barinthus Biotherapeutics has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Barinthus Biotherapeutics' return on equity of -54.70% beat Caribou Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Barinthus BiotherapeuticsN/A -54.70% -44.75% Caribou Biosciences -1,800.93%-62.35%-49.65% Does the media prefer BRNS or CRBU? In the previous week, Barinthus Biotherapeutics had 10 more articles in the media than Caribou Biosciences. MarketBeat recorded 10 mentions for Barinthus Biotherapeutics and 0 mentions for Caribou Biosciences. Barinthus Biotherapeutics' average media sentiment score of 0.37 beat Caribou Biosciences' score of -1.19 indicating that Barinthus Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Barinthus Biotherapeutics Neutral Caribou Biosciences Negative Do analysts recommend BRNS or CRBU? Barinthus Biotherapeutics currently has a consensus price target of $3.00, suggesting a potential upside of 107.56%. Caribou Biosciences has a consensus price target of $6.67, suggesting a potential upside of 193.69%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Barinthus Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Barinthus Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has more volatility and risk, BRNS or CRBU? Barinthus Biotherapeutics has a beta of -0.71, meaning that its share price is 171% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500. Do institutionals & insiders have more ownership in BRNS or CRBU? 25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 10.7% of Barinthus Biotherapeutics shares are held by company insiders. Comparatively, 8.3% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has higher valuation & earnings, BRNS or CRBU? Barinthus Biotherapeutics has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBarinthus Biotherapeutics$14.97M3.93-$61.07M-$1.73-0.84Caribou Biosciences$9.99M21.16-$149.10M-$1.78-1.28 SummaryBarinthus Biotherapeutics beats Caribou Biosciences on 10 of the 16 factors compared between the two stocks. Get Barinthus Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BRNS vs. The Competition Export to ExcelMetricBarinthus BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$58.85M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio-0.8422.1486.8826.71Price / Sales3.93458.33605.32131.81Price / CashN/A47.8637.9061.31Price / Book0.459.9312.556.55Net Income-$61.07M-$52.80M$3.31B$277.50M7 Day Performance18.47%5.22%4.28%2.42%1 Month Performance16.56%10.61%6.90%8.63%1 Year Performance8.68%25.03%70.54%31.60% Barinthus Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BRNSBarinthus Biotherapeutics2.5912 of 5 stars$1.45+1.8%$3.00+107.6%+8.7%$58.85M$14.97M-0.84107News CoverageShort Interest ↑CRBUCaribou Biosciences2.0114 of 5 stars$1.86-3.6%$6.67+258.4%+21.4%$179.73M$9.99M-1.04100Gap UpVORVor Biopharma1.0497 of 5 stars$31.28+12.0%N/AN/A$176.95MN/A-0.11140Short Interest ↓MISTMilestone Pharmaceuticals1.8186 of 5 stars$1.93-4.0%$4.50+133.2%+40.7%$170.84M$1M-2.3030IPHAInnate Pharma2.6867 of 5 stars$1.82-0.8%$6.50+258.1%-5.0%$168.70M$21.77M0.00220ACTUActuate Therapeutics1.5007 of 5 stars$6.88-3.0%$20.33+195.5%-6.4%$164.79MN/A0.0010ENTAEnanta Pharmaceuticals4.0644 of 5 stars$7.17-6.9%$20.20+181.7%-9.5%$164.61M$67.64M-1.66160News CoverageAnalyst ForecastAnalyst RevisionTVGNTevogen Bio2.1742 of 5 stars$0.80-4.2%$10.00+1,150.0%+141.5%$164.33MN/A-4.213Gap DownNVCTNuvectis Pharma3.2775 of 5 stars$6.00-6.7%$15.33+155.6%-1.5%$163.69MN/A-5.138GLSIGreenwich LifeSciences1.1269 of 5 stars$10.98-6.9%$42.00+282.5%-20.6%$160.84MN/A-8.073News CoverageNLTXNeoleukin TherapeuticsN/A$16.98-1.3%N/A-54.0%$159.58MN/A-5.4690High Trading Volume Related Companies and Tools Related Companies CRBU Competitors VOR Competitors MIST Competitors IPHA Competitors ACTU Competitors ENTA Competitors TVGN Competitors NVCT Competitors GLSI Competitors NLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BRNS) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Barinthus Biotherapeutics PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Barinthus Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BRNS Stock Alerts